{'fraction_non_alphanumeric': 0.02782608695652174, 'fraction_numerical': 0.02782608695652174, 'mean_word_length': 6.111111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The NK‐2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma

When stimulated, excitatory nonadrenergic noncholinergic (e‐NANC) nerves locally release tachykinins like Neurokinin (NK) A and Substance P, causing neurogenic inflammation and airway obstruction via activation of specific NK‐1 and NK‐2 receptors. The recently developed nonpeptide NK‐2 receptor antagonist SR 48968C has a high affinity for the NK‐2 receptor, and is a strong and selective antagonist of NK‐2 receptor mediated airway obstruction.